<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70376">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01750541</url>
  </required_header>
  <id_info>
    <org_study_id>SB-021</org_study_id>
    <secondary_id>MOH-021</secondary_id>
    <nct_id>NCT01750541</nct_id>
  </id_info>
  <brief_title>Haloperidol vs. Valproate in Agitation</brief_title>
  <official_title>Haloperidol vs. Valproate in the Management of Agitated Patients Presenting to the Emergency Department: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti Medical University</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of haloperidol and valproate in management
      of people with agitation in emergency department
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction in Agitated Behavior Scale (ABS) score</measure>
    <time_frame>within the first  30 minutes of treatment onset</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients were rated before medication administration and within 30 minutes afterwards according to Agitated Behavior Scale (ABS) score. Any statistically significant change in ABS score consider as positive effect of either intervention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Psychomotor Agitation</condition>
  <arm_group>
    <arm_group_label>Haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Haloperidol 5mg intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valproate single Infusion; 400 mg (weigh&lt;60 kg), 500 mg (weight&gt;60 Kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <arm_group_label>Haloperidol</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate</intervention_name>
    <arm_group_label>Valproate</arm_group_label>
    <other_name>Depakene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of psychomotor agitation

          -  aged 18 to 65 years

        Exclusion Criteria:

          -  Pregnant patients

          -  Severe liver disease

          -  History of drug (haloperidol/valproate) allergy

          -  Readily amendable causes for the agitation (hypoxemia or hypoglycemia)

          -  Hypotension (systolic blood pressure (SBP) â‰¤ 90 mm Hg)

          -  Known history of liver disease or uncontrolled diabetes

          -  Noticeable or suspected head trauma

          -  Previous history of neuroleptic malignant syndrome

          -  Receiving psychotropic medication, neuroleptic agents or cholinesterase inhibitors at
             the time of enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamran Heydari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Emergency Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Emergency Medicine, Imam Hossein Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>1617763141</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 5, 2013</lastchanged_date>
  <firstreceived_date>December 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shaheed Beheshti Medical University</investigator_affiliation>
    <investigator_full_name>Dr. Kamran Heydari</investigator_full_name>
    <investigator_title>Assistant Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
